ភាគហ៊ុនរបស់ Viking Therapeutics កើនឡើងបន្ទាប់ពី Madrigal ចែករំលែកទិន្នន័យវិជ្ជមានអំពីថ្នាំថ្លើមរបស់វា។

Shares of Viking Therapeutics Inc.
VKTX,
+ 77.61%
jumped 55% in premarket trading on Monday after a company that is also developing a selective thyroid hormone receptor beta agonist as a treatment for non-alcoholic steatohepatitis (NASH) and fibrosis announced positive, late-stage data. Madrigal Pharmaceuticals Inc.
MDGL,
+ 234.03%
បាននិយាយកាលពីថ្ងៃច័ន្ទ it is aiming to get an accelerated approval in the U.S. for its drug. Viking’s treatment candidate is currently in a Phase 2b clinical trial. The company’s stock is down 24.7% so far this year, while the broader S&P 500
SPX,
-0.61​%
បានធ្លាក់ចុះ 19.1% ។